NECTIN4 and neoplasm: The results of our in vivo efficacy study, conducted on nude mice carrying NCI-N87 human tumor xenografts, indicate that the high dose (10 mg/kg) of Nectin-4 NDC achieved complete tumor regression, displaying a dose-dependent trend.